Analysts Set CytomX Therapeutics, Inc. (NASDAQ:CTMX) Price Target at $6.67

Shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX) have earned an average recommendation of “Moderate Buy” from the seven research firms that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating and six have issued a buy rating on the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $6.6667.

A number of equities research analysts recently weighed in on CTMX shares. HC Wainwright raised their target price on shares of CytomX Therapeutics from $5.00 to $10.00 and gave the company a “buy” rating in a research note on Tuesday, November 11th. Weiss Ratings raised shares of CytomX Therapeutics from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, October 8th. Cantor Fitzgerald initiated coverage on shares of CytomX Therapeutics in a research report on Monday, September 22nd. They issued an “overweight” rating and a $6.00 target price for the company. Wedbush reissued an “outperform” rating and issued a $6.00 target price on shares of CytomX Therapeutics in a research note on Friday, November 7th. Finally, Wall Street Zen lowered CytomX Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th.

Institutional Trading of CytomX Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of CTMX. Orbimed Advisors LLC purchased a new position in shares of CytomX Therapeutics during the second quarter worth approximately $19,208,000. Commodore Capital LP bought a new position in shares of CytomX Therapeutics during the 2nd quarter valued at $17,462,000. Perceptive Advisors LLC purchased a new position in CytomX Therapeutics in the 2nd quarter worth $15,876,000. Vivo Capital LLC purchased a new position in CytomX Therapeutics in the 2nd quarter worth $13,096,000. Finally, Franklin Resources Inc. bought a new stake in CytomX Therapeutics in the second quarter worth $13,096,000. Hedge funds and other institutional investors own 67.77% of the company’s stock.

CytomX Therapeutics Stock Performance

Shares of CTMX stock opened at $4.16 on Friday. The company has a market capitalization of $704.85 million, a PE ratio of 10.40 and a beta of 2.37. CytomX Therapeutics has a 52-week low of $0.40 and a 52-week high of $4.62. The business’s fifty day moving average is $3.93 and its 200 day moving average is $2.96.

CytomX Therapeutics (NASDAQ:CTMX) last announced its earnings results on Thursday, November 6th. The biotechnology company reported ($0.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.05). The business had revenue of $5.96 million during the quarter, compared to the consensus estimate of $11.50 million. CytomX Therapeutics had a return on equity of 44.49% and a net margin of 24.66%. On average, sell-side analysts forecast that CytomX Therapeutics will post -0.05 EPS for the current fiscal year.

About CytomX Therapeutics

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics based on its proprietary Probody® platform. The company engineers masked antibody prodrugs that remain inactive in healthy tissue but are selectively activated in the tumor microenvironment. This approach is designed to enhance the safety and tolerability of antibody-based therapies, particularly those targeting immuno-oncology pathways.

At the core of CytomX’s pipeline is Pacmilimab (CX-072), an anti–PD-L1 Probody therapeutic currently undergoing clinical evaluation for multiple solid tumor indications.